- 90141-22-3[2,2'-Binaphthalene]-8,8'-dicarboxaldehyde,1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (2R)-
- 90-14-2Naphthalene, 1-iodo-
- 9014-25-9tRNA
- 90145-48-52-Pyridinecarboxamide,5-bromo-
- 9014-63-5Xylan
- 90147-43-6Withania somnifera,ext.
- 9014-74-8Peptidase, entero-
- 90147-49-2Yam, Dioscorea villosa,ext.
- 90147-57-2Yucca, ext.
Hot Products
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
- 7631-86-9Silicon dioxide
- 302-79-4Tretinoin
- 77-92-9Citric acid
|
Basic Information |
|
Post buying leads |
|
Suppliers |
| Name |
Neocarzinostatin |
EINECS | N/A |
| CAS No. | 9014-02-2 | Density | 1.52g/cm3 |
| PSA | 174.77000 | LogP | 1.85820 |
| Solubility | N/A | Melting Point |
260° (dec) |
| Formula | C35H35NO12 | Boiling Point | 900.5°C at 760 mmHg |
| Molecular Weight | 661.6519 | Flash Point | 498.4°C |
| Transport Information | N/A | Appearance | N/A |
| Safety | A deadly poison by ingestion, intraperitoneal, subcutaneous, and intravenous routes. An experimental teratogen. Experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits acrid smoke and irritating fumes. | Risk Codes | N/A |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
Zinostatinum;Neocarzinostatin; |
Neocarzinostatin Chemical Properties
Chemistry informtion about Neocarzinostatin (9014-02-2) is:
Synonyms: a8544527g1 ; neocarcinostatin ; neocarzinostatink ; neocarzinostatin from streptomyces carzinostaticus ; NSC-157365
MF:C35H33NO12
Storage temp. :2-8°C
Following is the molecular structure of Neocarzinostatin (9014-02-2) is:
Neocarzinostatin Uses
Neocarzinostatin (9014-02-2) can be used as a medicine, and in Japan only it has been used against liver cancer clinically.
Neocarzinostatin Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
| dog | LDLo | intraperitoneal | 1mg/kg (1mg/kg) | Behavioral: somnolence (general depressed activity) behavioral: tremor gastrointestinal: nausea or vomiting | Kiso to Rinsho. Clinical Report. Vol. 10, Pg. 610, 1976. |
| dog | LDLo | intravenous | 200ug/kg (0.2mg/kg) | Behavioral: somnolence (general depressed activity)behavioral: food intake (animal) | Kiso to Rinsho. Clinical Report. Vol. 10, Pg. 610, 1976. |
| mouse | LD50 | intraperitoneal | 1720ug/kg (1.72mg/kg) | Gastrointestinal: alteration in gastric secretion blood: changes in spleen | Journal of Antibiotics. Vol. 31, Pg. 468, 1978. |
| mouse | LD50 | intravenous | 960ug/kg (0.96mg/kg) | Behavioral: somnolence (general depressed activity) behavioral: food intake (animal) skin and appendages (skin): hair: other | Journal of Antibiotics. Vol. 28, Pg. 64, 1975. |
| mouse | LD50 | oral | 1050mg/kg (1050mg/kg) | Behavioral: somnolence (general depressed activity) behavioral: food intake (animal) skin and appendages (skin): hair: other | Journal of Antibiotics. Vol. 28, Pg. 64, 1975. |
| mouse | LD50 | subcutaneous | 7200ug/kg (7.2mg/kg) | Behavioral: altered sleep time (including change in righting reflex) gastrointestinal: "hypermotility, diarrhea" skin and appendages (skin): hair: other | Oyo Yakuri. Pharmacometrics. Vol. 11, Pg. 309, 1976. |
| rabbit | LD50 | intravenous | 900ug/kg (0.9mg/kg) | | Journal of Antibiotics. Vol. 28, Pg. 64, 1975. |
| rabbit | LD50 | oral | > 600mg/kg (600mg/kg) | | Journal of Antibiotics. Vol. 28, Pg. 64, 1975. |
| rat | LD50 | intraperitoneal | 940ug/kg (0.94mg/kg) | Behavioral: altered sleep time (including change in righting reflex) gastrointestinal: "hypermotility, diarrhea" skin and appendages (skin): hair: other | Oyo Yakuri. Pharmacometrics. Vol. 11, Pg. 309, 1976. |
| rat | LD50 | intravenous | 830ug/kg (0.83mg/kg) | | Journal of Antibiotics. Vol. 28, Pg. 64, 1975. |
| rat | LD50 | subcutaneous | 4980ug/kg (4.98mg/kg) | Behavioral: altered sleep time (including change in righting reflex) gastrointestinal: "hypermotility, diarrhea" skin and appendages (skin): hair: other | Oyo Yakuri. Pharmacometrics. Vol. 11, Pg. 309, 1976. |
| rat | LDLo | oral | 300mg/kg (300mg/kg) | Behavioral: altered sleep time (including change in righting reflex) gastrointestinal: "hypermotility, diarrhea" skin and appendages (skin): hair: other | Oyo Yakuri. Pharmacometrics. Vol. 11, Pg. 309, 1976. |
Neocarzinostatin Specification
Neocarzinostatin (9014-02-2) is a macromolecular chromoprotein Enediyne antibiotic with anti-tumoral activity secreted by Streptomyces macromomyceticus. It consists of two parts, a labile chromophore (bicyclic dienediyne structure shown at right) and a 113 amino acid apoprotein to which the chromophore is tightly and non-covalently bound with high affinity (Kd ~ 10-10 M). The chromophore is a very potent DNA-damaging agent; it is very labile and the role of the apoprotein is to protect it and release it to the target DNA. Opening of the epoxide under reductive conditions present in cells creates favorable conditions for a Bergman_cyclization, leading to a diradical intermediate and eventually double DNA strand cleavage. Other members of the neocarzinostatin group of antibiotics are macromomycin, actinoxanthin, kedarcidin and maduropeptin.
What can I do for you?
Get Best Price
